Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03629249 · ClinicalTrials.gov registry record · Phase 3
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
NCT03629249 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 604 participants.
The verdict
NCT03629249, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
Study Summary
The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over 52 weeks.
Interventions
- DRUG Placebo once daily
- DRUG QAW039 150 mg once daily
- DRUG QAW039 450 mg once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2020-02-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03629249
The ClinicalTrials.gov registry entry for NCT03629249 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo once daily is the first listed.
NCT03629249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03629249 about?
NCT03629249 is a clinical study titled "Systemic Corticosteroids Avoidance Study in Severe Asthma Patients". The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over 52 weeks.
What is the current status of trial NCT03629249?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2018-12-13. Estimated completion is 2020-02-06.
What interventions are being tested in trial NCT03629249?
The interventions under investigation include: Placebo once daily (DRUG), QAW039 150 mg once daily (DRUG), QAW039 450 mg once daily (DRUG).
Who is sponsoring clinical trial NCT03629249?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.